Results 41 to 50 of about 26,582 (250)

Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews

Advances in Rheumatology, 2020
Background Duloxetine and amitriptyline are antidepressants used in the treatment of fibromyalgia. In published systematic reviews, there is no agreement about which drug is more effective and safer.
Áurea Dias de Farias, Luciana Eberle, Tânia Alves Amador, Tatiane da Silva Dal Pizzol   +3 more
doaj   +1 more source

Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT

Health Technology Assessment, 2022
Background: The mainstay of treatment for diabetic peripheral neuropathic pain is pharmacotherapy, but the current National Institute for Health and Care Excellence guideline is not based on robust evidence, as the treatments and their combinations have ...
Solomon Tesfaye, Gordon Sloan, Jennifer Petrie, David White, Mike Bradburn, Tracey Young, Satyan Rajbhandari, Sanjeev Sharma, Gerry Rayman, Ravikanth Gouni, Uazman Alam, Steven A Julious, Cindy Cooper, Amanda Loban, Katie Sutherland, Rachel Glover, Simon Waterhouse, Emily Turton, Michelle Horspool, Rajiv Gandhi, Deirdre Maguire, Edward Jude, Syed Haris Ahmed, Prashanth Vas, Christian Hariman, Claire McDougall, Marion Devers, Vasileios Tsatlidis, Martin Johnson, Didier Bouhassira, David L Bennett, Dinesh Selvarajah   +31 more
doaj   +1 more source

Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database

British Journal of Clinical Pharmacology, EarlyView.
Aims Globally, Australia has the highest per capita consumption rate of pregabalin, commonly prescribed for neuropathic pain. Emerging evidence suggests pregabalin may be associated with the onset or recurrence of several potentially life‐threatening psychiatric events in some individuals.
Amy G. McNeilage, Ali Gholamrezaei, Bridin Murnion, Suzanne Nielsen, Claire E. Ashton‐James   +4 more
wiley   +1 more source

Amitriptyline induced cervical dystonia

Journal of the Scientific Society, 2016
Tricyclic antidepressants (TCAs), such as amitriptyline, have many side effects. But extrapyramidal tract symptom is an uncommon side effect of these drugs. Here, we report a case of a 28-year-old male who is suffering from amitriptyline induced cervical
Shivanand B Hiremath, Mahesh Desai
doaj   +1 more source

Examination and characterisation of the effect of amitriptyline therapy for chronic neuropathic pain on neuropeptide and proteomic constituents of human cerebrospinal fluid

Brain, Behavior, & Immunity - Health, 2021
Introduction: Amitriptyline is prescribed to reduce the intensity of chronic neuropathic pain. There is a paucity of validated in vivo evidence in humans regarding amitriptyline’s mechanism of action.
Jonathan Royds, Hilary Cassidy, Melissa J. Conroy, Margaret R. Dunne, Joanne Lysaght, Connail McCrory   +5 more
doaj   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

British Journal of Clinical Pharmacology, EarlyView.
Aims To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week.
Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef   +5 more
wiley   +1 more source

Expanding the Phenotype of CYFIP2‐Related Developmental Epileptic Encephalopathy: Case Report and Literature Review

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Background Pathogenic CYFIP2 variants cause developmental and epileptic encephalopathy (DEE), characterized by early‐onset intractable epilepsy and developmental delay. The disease course has not been delineated. Codon Arg87 is a de novo mutational hotspot associated with a severe DEE phenotype via gain‐of‐function mechanisms. Currently, there
Michaela Squire, Jenna K. Lea, Zheng (Jane) Fan, Senyene E. Hunter   +3 more
wiley   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Modulation of nociception by amitriptyline hydrochloride in the Speke’s hinge‐back tortoise (Kiniskys spekii)

Veterinary Medicine and Science, 2021
Background There are limited studies on the utilization of analgesics in testudines. Management of pain in reptiles is by use of analgesics generally used in other vertebrate species.
Christopher M. Makau, Philemon K. Towett, Klas S.P. Abelson, Titus I. Kanui   +3 more
doaj   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source